Verily Life Sciences LLC, South San Francisco, California, USA
Verily Life Sciences LLC, South San Francisco, California, USA.
BMJ Open. 2022 Jan 4;12(1):e054741. doi: 10.1136/bmjopen-2021-054741.
We assessed the relationship between the Patient Health Questionnaire-9 (PHQ-9) at intake and other measurements intended to assess biological factors, markers of disease and health status.
DESIGN, SETTING AND PARTICIPANTS: We performed a cross-sectional analysis of 2365 participants from the Baseline Health Study, a prospective cohort of adults selected to represent major demographic groups in the USA. Participants underwent deep phenotyping on demographic, clinical, laboratory, functional and imaging findings.
Despite extensive research on the clinical implications of the PHQ-9, data are limited on the relationship between PHQ-9 scores and other measures of health and disease; we sought to better understand this relationship.
None.
Cross-sectional measures of medical illnesses, gait, balance strength, activities of daily living, imaging and laboratory tests.
Compared with lower PHQ-9 scores, higher scores were associated with female sex (46.9%-66.7%), younger participants (53.6-42.4 years) and compromised physical status (higher resting heart rates (65 vs 75 bpm), larger body mass index (26.5-30 kg/m), greater waist circumference (91-96.5 cm)) and chronic conditions, including gastro-oesophageal reflux disease (13.2%-24.7%) and asthma (9.5%-20.4%) (p<0.0001). Increasing PHQ-9 score was associated with a higher frequency of comorbidities (migraines (6%-20.4%)) and active symptoms (leg cramps (6.4%-24.7%), mood change (1.2%-47.3%), lack of energy (1.2%-57%)) (p<0.0001). After adjustment for relevant demographic, socioeconomic, behavioural and medical characteristics, we found that memory change, tension, shortness of breath and indicators of musculoskeletal symptoms (backache and neck pain) are related to higher PHQ-9 scores (p<0.0001).
Our study highlights how: (1) even subthreshold depressive symptoms (measured by PHQ-9) may be indicative of several individual- and population-level concerns that demand more attention; and (2) depression should be considered a comorbidity in common disease.
NCT03154346.
我们评估了患者健康问卷-9（PHQ-9）在摄入时与其他旨在评估生物学因素、疾病标志物和健康状况的测量值之间的关系。
设计、地点和参与者：我们对来自基础健康研究的 2365 名参与者进行了横断面分析，这是一个前瞻性的成年人队列，旨在代表美国主要人口群体。参与者接受了关于人口统计学、临床、实验室、功能和影像学发现的深入表型分析。
尽管对 PHQ-9 的临床意义进行了广泛的研究，但关于 PHQ-9 评分与其他健康和疾病测量值之间的关系的数据有限；我们试图更好地理解这种关系。
无。
医疗疾病、步态、平衡力量、日常生活活动、影像学和实验室检查的横断面测量值。
与较低的 PHQ-9 评分相比，较高的评分与女性（46.9%-66.7%）、年轻参与者（53.6-42.4 岁）和身体状况受损（更高的静息心率（65 比 75 次/分）、更大的体重指数（26.5-30kg/m）、更大的腰围（91-96.5cm））和慢性疾病相关，包括胃食管反流病（13.2%-24.7%）和哮喘（9.5%-20.4%）（p<0.0001）。PHQ-9 评分的升高与共病的频率增加（偏头痛（6%-20.4%））和活动性症状（腿部痉挛（6.4%-24.7%）、情绪变化（1.2%-47.3%）、精力不足（1.2%-57%））（p<0.0001）相关。在调整相关的人口统计学、社会经济、行为和医疗特征后，我们发现记忆变化、紧张、呼吸急促和肌肉骨骼症状指标（背痛和颈部疼痛）与较高的 PHQ-9 评分相关（p<0.0001）。
我们的研究强调了以下几点：（1）即使是亚阈值抑郁症状（通过 PHQ-9 测量）也可能表明存在一些需要更多关注的个体和人群问题；（2）抑郁应被视为常见疾病的一种合并症。
NCT03154346。
